---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021838"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:33:19.834340+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q3 net loss $35.4M; revumenib Phase 1 shows 30% CR/CRh rate, 9.1 mo median durability

## Summary
- Net loss $35.4M ($0.58 per share) vs $20.6M ($0.40) prior year; cash $337.8M at Sep 30.
- Revumenib Phase 1 CR/CRh rate 30% (18/60); median response 9.1 months; 75% of transplanted patients in remission.
- Enrollment complete in pivotal AGAVE-201 trial of axatilimab in cGVHD; topline data expected mid-2023.
- Lowered FY 2022 R&D expense guidance to $115-125M and total op ex to $145-155M, citing axatilimab cost sharing.
- On track for revumenib NDA and axatilimab BLA filings by end of 2023.

## SEC filing metadata
- accession: 0000950170-22-021838
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/0000950170-22-021838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/sndx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021838
- JSON: https://secwatch.observer/filing/0000950170-22-021838.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021838.txt

## Key facts
- Earnings Releases
  Syndax Pharmaceuticals Inc reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1395937/000095017022021838/0000950170-22-021838-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.